180 related articles for article (PubMed ID: 29076241)
21. Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks.
Arendt M; Nasir L; Morgan IM
Vet Comp Oncol; 2009 Sep; 7(3):153-61. PubMed ID: 19691644
[TBL] [Abstract][Full Text] [Related]
22. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
23. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
24. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.
El-Sherbiny YM; Holmes TD; Wetherill LF; Black EV; Wilson EB; Phillips SL; Scott GB; Adair RA; Dave R; Scott KJ; Morgan RS; Coffey M; Toogood GJ; Melcher AA; Cook GP
Clin Exp Immunol; 2015 Apr; 180(1):98-107. PubMed ID: 25469725
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
Gujar SA; Clements D; Dielschneider R; Helson E; Marcato P; Lee PW
Br J Cancer; 2014 Jan; 110(1):83-93. PubMed ID: 24281006
[TBL] [Abstract][Full Text] [Related]
28. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
[TBL] [Abstract][Full Text] [Related]
29. Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.
Campion CA; Soden D; Forde PF
BMC Cancer; 2016 Jul; 16():462. PubMed ID: 27412241
[TBL] [Abstract][Full Text] [Related]
30. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
31. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
[TBL] [Abstract][Full Text] [Related]
32. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma.
Alloussi SH; Alkassar M; Urbschat S; Graf N; Gärtner B
Oncol Rep; 2011 Sep; 26(3):645-9. PubMed ID: 21637921
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
[TBL] [Abstract][Full Text] [Related]
34. Modification of mammalian reoviruses for use as oncolytic agents.
Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
[TBL] [Abstract][Full Text] [Related]
35. Reovirus-based therapy for cancer.
Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
[TBL] [Abstract][Full Text] [Related]
36. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic virotherapy of canine and feline cancer.
Gentschev I; Patil SS; Petrov I; Cappello J; Adelfinger M; Szalay AA
Viruses; 2014 May; 6(5):2122-37. PubMed ID: 24841386
[TBL] [Abstract][Full Text] [Related]
38. Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.
Zhao X; Chester C; Rajasekaran N; He Z; Kohrt HE
Mol Cancer Ther; 2016 May; 15(5):767-73. PubMed ID: 27197256
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.
Patil SS; Gentschev I; Nolte I; Ogilvie G; Szalay AA
J Transl Med; 2012 Jan; 10():3. PubMed ID: 22216938
[TBL] [Abstract][Full Text] [Related]
40. Reovirus: Rationale and clinical trial update.
Lal R; Harris D; Postel-Vinay S; de Bono J
Curr Opin Mol Ther; 2009 Oct; 11(5):532-9. PubMed ID: 19806501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]